Viewing Study NCT03620669

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:58 PM
Ignite Modification Date: 2026-06-27 @ 3:35 AM
Study NCT ID: NCT03620669
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-15
First Post: 2018-07-03
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: 1st Line Durvalumab in PS 2 NSCLC Patients
Sponsor: Swiss Cancer Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None NSCLC Stage IV View
None NSCLC Stage IIIB View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Lung cancer View
None Durvalumab View
None PD-L1 View
None NSCLC View
None Phase II View
None PS 2 View